Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns a combination with durvalumab for the maintenance treatment of mismatch repair proficient primary advanced or recurrent endometrial cancer
Findings from the HD21 study
Evidence for efficacy is based on the results from the KRYSTAL-1 study
Findings from the innovaTV 301/ENGOT-cx12/GOG-3057 study
Findings from the IMROZ and BENEFIT studies
It is intended for the treatment of patients with urothelial carcinoma harbouring FGFR3 alterations
Final results of the COMBI-AD study
Evidence for efficacy is based on the results from the TRIDENT-1 study
Findings from the MARIPOSA study
Findings from the INTUITT-NF2 study
Findings from the DREAMM-7 and DREAMM-8 studies
Evidence for efficacy is based on the results from the LIBRETTO-001 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
